Tanvex BioPharma Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Stephen Lam

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Aug 07

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24

CEO

Stephen Lam

less than a year

Görev süresi

Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Lam	Chief Executive Officer	less than a year	Veri yok	Veri yok
Allen Chao	Founder & Honorary Chairman	no data	NT$111.00k	0.87% NT$ 88.9m
Wen Yeh	Chief Financial Officer	less than a year	Veri yok	Veri yok
Val Chen	VP of Finance Director of Ops. Mgmt.	no data	Veri yok	Veri yok
James Williamson	Accounting Officer	less than a year	Veri yok	Veri yok
Zheng Xia	Chief Technology Officer	9.9yrs	Veri yok	Veri yok
Linda Grillo	Director of Sales & Marketing	no data	Veri yok	Veri yok
Hsun-Chiang Hsieh	Secretary	no data	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 6541 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Allen Chao	Founder & Honorary Chairman	11.4yrs	NT$111.00k	0.87% NT$ 88.9m
David Hsia	Director	9.5yrs	Veri yok	0.50% NT$ 50.7m
Lin-Cheng Chen	Chairman	less than a year	NT$5.00k	Veri yok
Chi-Chuan Chen	Director	11.1yrs	NT$25.00k	0.010% NT$ 1.0m
Tamon Tseng	Director	11.1yrs	NT$25.00k	Veri yok
Jin-Pau Tsai	Independent Director	9.5yrs	NT$682.00k	Veri yok
Tay-Chang Wang	Independent Director	3.3yrs	NT$687.00k	Veri yok
Jang-Yang Chang	Independent Director	2.4yrs	NT$570.00k	Veri yok
Shang-Hsien Hsieh	Independent Director	less than a year	Veri yok	Veri yok
Chi-feng Chang	Independent Director	less than a year	Veri yok	Veri yok
Chun-Yen Chang	Independent Director	2.4yrs	NT$622.00k	Veri yok

3.3yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6541 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Tanvex BioPharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Recent updates

Tanvex BioPharma, Inc. to Report Q3, 2024 Results on Nov 08, 2024

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

Second quarter 2024 earnings released: NT$2.31 loss per share (vs NT$3.89 loss in 2Q 2023)

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Tanvex BioPharma, Inc. to Report Q2, 2024 Results on Aug 09, 2024

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

First quarter 2024 earnings released: NT$3.12 loss per share (vs NT$5.17 loss in 1Q 2023)

Tanvex BioPharma, Inc. to Report Q1, 2024 Results on May 07, 2024

Tanvex BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of TWD 1.44 billion.

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: NT$16.58 loss per share (vs NT$13.96 loss in FY 2022)

New major risk - Financial position

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer

Tanvex BioPharma, Inc. Announces Change of Chairman

Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer

Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer

Tanvex BioPharma, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Second quarter 2023 earnings released: NT$3.89 loss per share (vs NT$3.63 loss in 2Q 2022)

New minor risk - Shareholder dilution

Tanvex BioPharma, Inc. announced that it expects to receive TWD 220 million in funding

Less than half of directors are independent

Tanvex BioPharma, Inc. announced a financing transaction

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

Less than half of directors are independent

Tanvex BioPharma, Inc., Annual General Meeting, Jun 17, 2022

Tanvex BioPharma, Inc. Announces the Appointment of K. H. Lin as CFO and Accounting Officer, Effective from February 18, 2022

Price target decreased to NT$53.00

Price target increased to NT$67.00

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Tanvex BioPharma, Inc. Enters into A License Agreement with Amgen

New 90-day high: NT$44.95

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

New 90-day low: NT$36.55

New 90-day low: NT$37.15

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

New 90-day high: NT$45.95

Earnings miss expectations

New 90-day low - NT$37.00

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş